BioNTech launches public exchange offer to acquire CureVac shares

Rhea-AI Filing Summary

BioNTech SE announced the commencement of its public exchange offer for all outstanding shares of CureVac N.V., as disclosed in a press release furnished as Exhibit 99.1.

The report states this 6‑K is deemed filed and incorporated by reference into BioNTech’s registration statement on Form F-4 (File No. 333-289468) and its Forms S-8 (File Nos. 333-277105, 333-269740, 333-253263) from the filing date.

Insights

M&A analyst

BioNTech has begun an exchange offer for CureVac shares.

BioNTech disclosed it has commenced a public exchange offer for all outstanding shares of CureVac N.V.. The disclosure is accompanied by a press release (Exhibit 99.1) and is incorporated by reference into BioNTech’s Form F-4, indicating alignment with an existing registration framework for the transaction.

The filing does not specify consideration, timetable, or conditions in this excerpt. Actual transaction mechanics and any closing contingencies would be governed by the exchange offer documents and the F-4. Subsequent filings may provide additional details and progress updates.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF OCTOBER 2025

COMMISSION FILE NUMBER 001-39081

BioNTech SE

(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On October 22, 2025, BioNTech SE (the “Company”) issued a press release announcing the commencement of its exchange offer for all outstanding shares of CureVac N.V. A copy of the press release is attached hereto as Exhibit 99.1.

This report on Form 6-K shall be deemed to be filed and incorporated by reference in the Company’s registration statement on Form F-4 (File No. 333-289468) and registration statements on Form S-8 (File Nos. 333-277105, 333-269740 and 333-253263) and to be part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE
By:		/s/ Prof. Dr. Ugur Sahin				By:		/s/ Dr. Sierk Poetting
		Name: Prof. Dr. Ugur Sahin						Name: Dr. Sierk Poetting
		Title: Chief Executive Officer						Title: Chief Operating Officer

Date: October 22, 2025

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

FAQ

What did BioNTech (BNTX) announce in this 6-K?

BioNTech announced it commenced a public exchange offer for all outstanding shares of CureVac N.V., with details in Exhibit 99.1.

Which documents does this 6-K incorporate by reference for BNTX?

It is deemed filed and incorporated by reference into BioNTech’s Form F-4 (File No. 333-289468) and Forms S-8 (333-277105, 333-269740, 333-253263).

Where can I find more details about the exchange offer for CureVac?

The attached press release, Exhibit 99.1, provides further information on the exchange offer.

Does the filing specify the exchange ratio or consideration for CureVac shares?

This excerpt does not include consideration or exchange ratio details; see Exhibit 99.1 and the Form F-4 for terms.

Is this exchange offer limited to certain CureVac shareholders?

The disclosure states the offer is for all outstanding shares of CureVac N.V.